The dose-based price increases are a downside
It comes in three FDA-approved forms: Ozempic: weekly injection for type 2 diabetes (0.25 to 2.0 mg) Wegovy: weekly injection for obesity (0.25 to 2.4 mg), plus an oral tablet approved December 2025 (50 mg daily) Rybelsus: daily oral tablet for T2D (3, 7, or 14 mg) Off-label use of Ozempic for weight loss is common where insurance covers the diabetes indication but not the obesity one
But if Ozempic is working well for you and not causing you undesirable side effects, switching may not be in your best interest
As shown in Figure 7, since the filing of the main compound patents in 2006, Novo Nordisk has been applying for patents consistently over a period of 17 years, with heavier patenting activity in 2019, two years before Wegovy was approved
Trajectories of percentage BMI change during the 12 months after semaglutide initiation stratified by (A) semaglutide dose, (B) sex, (C) type 2 diabetes status, and (D) baseline BMI